Individual results may vary, so always consult a healthcare professional before starting treatment
Wegovy is administered as a once-weekly subcutaneous injection, with dosing gradually increased over time according to the recommended titration schedule to minimise gastrointestinal side effects
It alleviates hepatic injury by activating the Nrf2/HO-1 antioxidant pathway and suppressing NF-Bmediated inflammation, highlighting its potential as a therapeutic applicant for ALD (94)
[DOI] [PMC free article] [PubMed] [Google Scholar] 91.Vickram S., Rohini K., Srinivasan S., Veenakumari D.N., Archana K., Anbarasu K., Jeyanthi P., Thanigaivel S., Gulothungan G., Rajendiran N